Telix Pharmaceuticals (TLX) 46th Annual William Blair Growth Stock Conference summary

Company Overview and Strategy

• Operates as a global biopharma with over 1,000 employees, focused on radiopharmaceuticals and precision medicine, with commercial and R&D activities largely U.S.-based and a presence in 22+ countries.

• Emphasizes vertical integration, including just-in-time manufacturing, direct delivery, and a specialist commercial organization.

• Revenue from commercialized imaging agents funds ongoing R&D, reducing reliance on external capital.

• Strategic partnerships, such as with Regeneron, expand capabilities in antibody engineering and next-generation product development.

• Integrated theranostic approach combines diagnostics and therapeutics for precision medicine.

Product Portfolio and Regulatory Milestones

• Two FDA-approved PSMA imaging agents, Illuccix and Gozellix, are available in over 20 countries, driving significant revenue and market share, with further regulatory reviews ongoing in China and Japan.

• Gozellix offers next-generation PSMA-PET imaging with longer shelf-life and secured U.S. reimbursement.

• NDA submitted for Pixclara (glioblastoma imaging), with a PDUFA date set for September 2026; BLA resubmission for Zircaix (renal cancer imaging) in progress.

• BiPASS study may expand the addressable market for PSMA imaging, potentially adding 800,000 scans annually.

• Pipeline targets urologic oncology, neuro-oncology, and musculoskeletal cancers, with three phase III programs in prostate, kidney, and glioblastoma.

Financial Performance and Growth Outlook

• Achieved 16% quarter-over-quarter revenue growth in Q1 2026, reaching $186M in precision medicine sales.

• Near-term group revenue growth projected between 20% and 40% CAGR, with significant contributions expected from Pixclara, Zircaix, BiPASS, Gozellix, and Illuccix.

• Current product portfolio projected to reach AUD 2–2.5 billion in market opportunity over the next few years.

• Ex-U.S. business is accelerating, contributing to global revenue growth.

• Commercial success enables self-funded R&D and supports long-term revenue trajectory.